Anemia-Related Outcomes in Patients With CKD Treated With Dapagliflozin

Sponsor
Damanhour University
Study ID
NCT06813222
Status
Active Not Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

Anemia-Related Outcomes in Patients with CKD Treated with Dapagliflozin This study aims to identify factors that predict anemia improvement in chronic kidney disease (CKD) patients using Dapagliflozin, an SGLT2 inhibitor. Key questions: * What factors influence how well Dapagliflozin improves anemia in CKD patients? * Are there specific characteristics that predict better responses to Dapagliflozin treatment? The investigators will review medical records of CKD patients who started taking Dapagliflozin. The investigators will compare those with low hemoglobin levels (anemia) to those without anemia. The investigators will analyze: Changes in hemoglobin levels Other factors related to anemia (e.g., iron levels, TIBC, ferritin) Patient characteristics (e.g., age, sex, CKD stage) This study will help us understand which CKD patients are most likely to benefit from Dapagliflozin for anemia.

Key Dates

Start date
Apr 1, 2021
Status verified
Feb 2025
Primary completion
Mar 1, 2025
Completion
Mar 1, 2025

Study Design

Enrollment
100 participants (estimated)

Arms

  • Arm: Patients with diabetes and CKD receiving Dapagliflozin with and without anemia
    Anemia is defined as a baseline of Hb \<13.0 g/dl in males and \<12.0 g/dl in females
  • Arm: Patients with diabetes and CKD receiving antidiabetic drugs other than dapagliflozin
    Stable doses of antidiabetic agents (other than dapagliflozin) for ≥4 weeks prior to enrollment.

Primary Outcome Measure

Hemoglobin Changes [ Time Frame: 12 months ]

Related Studies